Literature DB >> 11684897

Problems and issues with door-to-door, two-phase surveys: an illustration from central Spain.

F Bermejo1, R Gabriel, S Vega, J M Morales, W A Rocca, D W Anderson.   

Abstract

In 1994-1995, a screening and examination survey was conducted to ascertain the prevalence of dementia, Parkinson's disease and stroke in two urban communities and one rural community of central Spain. We use this survey to illustrate many nonclinical aspects of conducting two-phase prevalence surveys. Special emphasis is given to two common weaknesses in such surveys: screening nonparticipation and screening validation. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2001        PMID: 11684897     DOI: 10.1159/000054794

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  17 in total

Review 1.  Screening questionnaires for parkinsonism: a systematic review.

Authors:  Nabila Dahodwala; Andrew Siderowf; Mona Baumgarten; Aaron Abrams; Jason Karlawish
Journal:  Parkinsonism Relat Disord       Date:  2011-09-17       Impact factor: 4.891

2.  Reported hearing impairment in essential tremor: a population-based case-control study.

Authors:  Julián Benito-León; Elan D Louis; Félix Bermejo-Pareja
Journal:  Neuroepidemiology       Date:  2007-12-13       Impact factor: 3.282

3.  The health status: the ignored risk factor in dementia incidence. NEDICES cohort.

Authors:  Félix Bermejo-Pareja; Agustín Gómez de la Cámara; Teodoro Del Ser; Israel Contador; Sara Llamas-Velasco; Jesús María López-Arrieta; Cristina Martín-Arriscado; Jesús Hernández-Gallego; Saturio Vega; Julián Benito-León
Journal:  Aging Clin Exp Res       Date:  2022-01-13       Impact factor: 3.636

4.  Population-based prospective study of cigarette smoking and risk of incident essential tremor.

Authors:  Elan D Louis; Julián Benito-León; Félix Bermejo-Pareja
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

5.  Prevalence of dementia and major dementia subtypes in Spanish populations: a reanalysis of dementia prevalence surveys, 1990-2008.

Authors:  Jesús de Pedro-Cuesta; Javier Virués-Ortega; Saturio Vega; Manuel Seijo-Martínez; Pedro Saz; Fernanda Rodríguez; Angel Rodríguez-Laso; Ramón Reñé; Susana Pérez de las Heras; Raimundo Mateos; Pablo Martínez-Martín; José María Manubens; Ignacio Mahillo-Fernandez; Secundino López-Pousa; Antonio Lobo; Jordi Llinàs Reglà; Jordi Gascón; Francisco José García; Manuel Fernández-Martínez; Raquel Boix; Félix Bermejo-Pareja; Alberto Bergareche; Julián Benito-León; Ana de Arce; José Luis del Barrio
Journal:  BMC Neurol       Date:  2009-10-19       Impact factor: 2.474

6.  Antihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES).

Authors:  Elan D Louis; Julián Benito-León; Félix Bermejo-Pareja
Journal:  Neuroepidemiology       Date:  2009-08-20       Impact factor: 3.282

7.  Rate of cognitive decline during the premotor phase of essential tremor: a prospective study.

Authors:  Julián Benito-León; Elan D Louis; Álvaro Sánchez-Ferro; Félix Bermejo-Pareja
Journal:  Neurology       Date:  2013-05-22       Impact factor: 9.910

8.  Philadelphia Geriatric Morale Scale in essential tremor: a population-based study in three Spanish communities.

Authors:  Elan D Louis; Julián Benito-León; Félix Bermejo-Pareja
Journal:  Mov Disord       Date:  2008-07-30       Impact factor: 10.338

9.  Physical activity and risk of Parkinson's disease and parkinsonism in a prospective population-based study (NEDICES).

Authors:  Sara Llamas-Velasco; Israel Contador; Antonio Méndez-Guerrero; Carmen Romero Ferreiro; Julián Benito-León; Alberto Villarejo-Galende; Félix Bermejo-Pareja
Journal:  Prev Med Rep       Date:  2021-07-08

Review 10.  Geographical variation in dementia: systematic review with meta-analysis.

Authors:  Tom C Russ; G David Batty; Gena F Hearnshaw; Candida Fenton; John M Starr
Journal:  Int J Epidemiol       Date:  2012-07-13       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.